MedPlus Health Services Limited
MEDPLUS.BO News Today: Stay Updated with the Latest MedPlus Health Services Limited News in Real Time
Find MEDPLUS.BO news now at Meyka AI. Stay informed with the latest MedPlus Health Services Limited stocks updates, including price news, market analysis, and expert insights.
^NDX Today April 01: H-1B Cap, New Rules Point to Rising Tech Labor Costs
USCIS H1B lottery 2027 closes as H-1B cap reached; DOL prevailing wage reforms could lift tech labor costs. What it means for margins, hiring, and ^NDX positioning today.
IDEA.NS Vodafone Idea (NSE) pre-market INR 8.64: most active with heavy volume
IDEA.NS stock pre-market update on 02 Apr 2026. Price INR 8.64, volume 664,598,626. Short-term forecast and Meyka AI grade
3GDX.AS jumps 23.94% to €13.06 on EURONEXT 01 Apr 2026: momentum may continue
3GDX.AS stock jumps 23.94% to €13.06 on EURONEXT; our analysis and Meyka forecast show notable upside for traders
Volume spike: PUM.SW stock CHF 21.88 on SIX 01 Apr 2026: 400x volume insight
PUM.SW stock saw a **400x** volume spike to **CHF 21.88** on SIX 01 Apr 2026 with mixed fundamentals and model downside
April 01: Unilever to Spin Off Food Unit in $44.8B McCormick Merger
Unilever McCormick merger: Unilever will spin off its food brands and combine them with McCormick via a $44.8B Reverse Morris Trust. What it means for Germany, investors, and timelines.
Yamana Gold (YRI.TO, TSX) C$7.89 on 23.62M shares 01 Apr 2026: 65.87% model upside
Intraday update on YRI.TO stock trading C$7.89 with heavy volume; Meyka AI forecast projects C$13.08 (65.87% upside)
APX.AX Appen up 4.38% pre-market ASX 02 Apr 2026: AI data demand shifts outlook
Pre-market ASX update on APX.AX stock at A$1.43; volume 4,678,534. Meyka grade, forecasts and price targets included
High volume lifts SAYFF stock on PNK 01 Apr 2026: Monitor liquidity and valuation
High-volume update on SAYFF stock on PNK 01 Apr 2026 — volume, valuation, Meyka AI score
UK Politics April 01: Labour Suspends Karl Turner, Justice Reform Risk
Labour suspends Karl Turner MP over criticism of jury trial reforms and comments about Morgan McSweeney, raising policy risk for UK justice. What investors should watch now.